ASCO 2024 | BASECAMP-1: a prescreening study for the EVEREST-1 and -2 trials in solid tumors
Caleb Smith, MD, Mayo Clinic, Rochester, MN, discusses the BASECAMP-1 prescreening study (NCT04981119), which aims to screen patients with solid tumors for the EVEREST-1 (NCT05736731) and -2 (NCT06051695) trials. The aforementioned trials will assess novel Tmod CAR T-cell therapies and patients with tumors with human leukocyte antigen-A*02 (HLA-A*02) loss of heterozygosity (LOH) are eligible. Expanding the HLA subtype to all HLA-A*02 subtypes resulted in increased diversity of enrolled patients. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Travel, Accommodations, Expenses – A2 Biotherapeutics
